| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 3 | 3 | 1 | 33% | +1.3% | +1.0% |
| 3d | 6 | 6 | 3 | 50% | +0.2% | -0.2% |
| 1w | 6 | 6 | 2 | 33% | +1.1% | +2.8% |
| 1m | 6 | 6 | 3 | 50% | -0.6% | -0.7% |
| 3m | 6 | 6 | 1 | 17% | +4.8% | +1.0% |
| 6m | 3 | 3 | 2 | 67% | +1.3% | +11.7% |
| 1y | 3 | 3 | 2 | 67% | -9.7% | +1.7% |
Past performance does not predict future results. Informational only, not investment advice.
Amazon's $220 billion capex spend is straining free cash flow and is unsustainable. Today's earnings could trigger a market repricing as investors finally demand returns on this heavy spending rather than granting bulls another reprieve.
Uber appears to be a value trap similar to PayPal and Adobe, where a cheap valuation masks deteriorating growth prospects and the inability to sustain margins. The author skeptically questions whether the stock's current price reflects genuine value or merely the illusion of cheapness, given the market's historical pattern of repricing such companies lower.
Google operates a diversified portfolio of dominant assets across search, cloud, AI, video, and autonomous vehicles while competing successfully against multiple tech giants simultaneously. Despite a $4.6 trillion valuation, the company's scale, network effects, and cash generation suggest it remains reasonably valued relative to its competitive moat and growth potential.
Microsoft is lagging while other Mag 7 stocks rally, and the market may be pricing in concerns about massive AI spending failing to deliver profitable returns. If Copilot adoption disappoints or enterprise customers slow their AI spending, MSFT risks a sharp breakdown despite the consensus view that it would win the AI race.
Google has demonstrated durable competitive moats across Search, YouTube, and Cloud despite repeated predictions of disruption. Strong earnings beats and scaling Cloud revenue show the company's core franchises remain highly profitable and resilient to AI competition.
Novo Nordisk gains a meaningful U.S. distribution channel for Ozempic/Wegovy through Costco's 600+ pharmacies before Eli Lilly's Zepbound competition ramps, providing real-world market expansion and durability to its GLP-1 franchise despite the current 40x valuation.
Costco's Ozempic/Wegovy partnership through its member prescription program at $499/month adds a low-margin, high-traffic revenue stream that strengthens the healthcare moat, increases membership renewal rates, and provides another consumption hook similar to its rotisserie chicken model. The $15B+ GLP-1 market expansion and pharmacy revenue growth (~15% y/y) support earnings durability despite current 45x valuation.
End of results.